CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Results were more profound in the CP-CML CD34+ cells when TKIs were used in combination with DOR, with significantly higher levels of apoptosis observed in the CP-CML CD34+ (Fig. 3A-i-ii); the synergistic effect was not observed with normal CD34+ cells (Suppl.